Natera (NASDAQ:NTRA) Stock: Insider Steven Leonard Chapman Sells 3,801 Shares

Posted by Geri Gentry on Nov 6th, 2026

Natera, Inc. (NASDAQ:NTRA – Get Free Report) CEO Steven Chapman sold 3,801 shares of the stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $411.80, for a total transaction of $1,565,251.80. Following the completion of the sale, the chief executive officer directly owned 87,431 shares of the company’s stock, valued at $36,004,085.80. The trade was a 4.17% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Steven Leonard Chapman also recently made the following trade(s):

On Wednesday, October 28th, Steven Chapman sold 3,430 shares of Natera stock. The shares were sold at an average price of $426.34, for a total transaction of $1,462,346.20.
On Tuesday, October 27th, Steven Chapman sold 2,264 shares of Natera stock. The shares were sold at an average price of $406.00, for a total transaction of $919,184.00.
On Thursday, October 1st, Steven Chapman sold 1,273 shares of Natera stock. The shares were sold at an average price of $413.31, for a total transaction of $526,143.63.
On Tuesday, September 1st, Steven Chapman sold 1,698 shares of Natera stock. The stock was sold at an average price of $320.99, for a total transaction of $545,041.02.

Natera Stock Down 7.0%

Shares of Natera stock opened at $363.76 on Friday. Natera, Inc. has a twelve month low of $181.00 and a twelve month high of $437.41. The company has a fifty day moving average price of $380.81 and a 200 day moving average price of $269.30.

Natera (NASDAQ:NTRA – Get Free Report) last released its quarterly earnings data on Thursday, November 5th. The medical research company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.14). Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The company had revenue of $793.98 million during the quarter, compared to analysts’ expectations of $707.54 million. During the same period last year, the business earned ($0.64) earnings per share. The company’s revenue for the quarter was up 34.1% compared to the same quarter last year. Equities research analysts expect that Natera, Inc. will post -1.14 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Natera

A number of institutional investors and hedge funds have recently added to or reduced their stakes in NTRA. Trust Co. of Vermont bought a new position in Natera during the 2nd quarter worth approximately $26,000. Elevation Wealth Partners LLC acquired a new position in shares of Natera in the 2nd quarter worth approximately $30,000. Continuum Advisory LLC acquired a new position in shares of Natera in the 2nd quarter worth approximately $33,000. Rakuten Securities Inc. bought a new stake in shares of Natera in the 2nd quarter valued at approximately $35,000. Finally, Burkett Financial Services LLC bought a new stake in shares of Natera in the 3rd quarter valued at approximately $57,000. 99.90% of the stock is owned by hedge funds and other institutional investors.

More Natera News

Here are the key news stories impacting Natera this week:

Positive Sentiment: Third-quarter revenue rose 34.1% year over year to $794.0 million, exceeding analyst expectations of about $707.5 million. The result points to continued business growth. Natera third-quarter 2026 results
Positive Sentiment: Medicare coverage for Signatera in hepatocellular carcinoma (HCC) could improve access to the test and support adoption of Natera’s oncology products. Medicare coverage for Signatera in HCC
Neutral Sentiment: Gross margin was 64.7%, nearly unchanged from 64.9% a year earlier, indicating that strong sales growth came with broadly stable margin performance. Natera third-quarter 2026 results
Neutral Sentiment: Several executives and insiders sold shares under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested equity awards. The sales may attract attention, but their stated purpose and scheduled nature make them less informative about management’s outlook. Natera insider transaction
Negative Sentiment: Natera reported a quarterly loss of $0.42 per share, wider than analysts’ expected loss of $0.28. The earnings miss likely outweighed the revenue beat and added pressure on the stock. Natera third-quarter 2026 results

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the company. Robert W. Baird set a $348.00 target price on Natera in a research note on Friday, August 7th. Barclays boosted their price target on Natera from $340.00 to $475.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 7th. Citigroup upped their price target on Natera from $365.00 to $480.00 and gave the stock a “buy” rating in a report on Tuesday, October 6th. Wells Fargo & Company upped their price target on Natera from $220.00 to $284.00 and gave the stock an “equal weight” rating in a report on Friday, August 7th. Finally, Roth Capital started coverage on shares of Natera in a research report on Thursday, October 22nd. They issued a “buy” rating and a $475.00 price objective for the company. Two analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $394.31.

Check Out Our Latest Report on Natera

Natera Company Profile

(Get Free Report)

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to provide personalized genetic and genomic information. Its tests are used across reproductive health, oncology and organ transplantation, with the company combining next-generation sequencing and bioinformatics to analyze DNA and monitor disease-related signals.

In reproductive health, Natera offers Panorama noninvasive prenatal screening, Horizon carrier screening and Vistara single-gene disorder screening.